Fundraising FoxGilead Sciences — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founders)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsAvoro Capital AdvisorsForesite CapitalTPGVida VenturesVVAG Special
Tmunity Therapeutics was a University of Pennsylvania spinout developing engineered T-cell therapies, including CAR-T and TCR-based treatments, for cancers.
BiotechPhiladelphia, US
Anne Chew(Director and President)
BoardKevin Mahoney(Director)
Co-investorsAndreessen HorowitzKhosla VenturesKleiner PerkinsLAVLilly Asia VenturesMilitia Hill Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.